PRODUCT USE ISSUE

Adverse reaction reported in 84,135 FDA reports across 53 drugs.

84,135

Total Reports

Drugs Involved

Infliximab

Most Reported Drug

Drugs Associated with PRODUCT USE ISSUE

Drugs where "PRODUCT USE ISSUE" was reported as an adverse event.

#	Drug	Reports	% of Total
1	Infliximab	13,296	15.8%
2	Dupilumab	10,648	12.7%
3	Polyethylene Glycol 3350	9,905	11.8%
4	Golimumab	6,215	7.4%
5	Ustekinumab	5,368	6.4%
6	Cortisone	3,531	4.2%
7	Pseudoephedrine	3,368	4.0%
8	Risperidone	2,785	3.3%
9	Propranolol	2,501	3.0%
10	Pembrolizumab	2,494	3.0%
11	Loratadine	2,088	2.5%
12	Adapalene	1,851	2.2%
13	Topiramate Spinkle	1,502	1.8%
14	Pimavanserin	1,417	1.7%
15	Lisdexamfetamine Dimesylate	1,303	1.5%
16	Gluconate	998	1.2%
17	Buprenorphine Hydrochloride, Naloxone Hydrochloride	978	1.2%
18	Minoxidil	862	1.0%
19	Progesterone	757	0.9%
20	Lacosamide	719	0.9%
21	Salicylic Acid	698	0.8%
22	Cenobamate	584	0.7%
23	Ticagrelor	546	0.6%
24	Mometasone Furoate / Formoterol Fumarate Dihydrate	542	0.6%
25	Rifaximin	506	0.6%
26	Brexpiprazole	501	0.6%
27	Clobazam	487	0.6%
28	Teduglutide	478	0.6%
29	Budesonide, Glycopyrrolate, / Formoterol Fumarate	456	0.5%
30	Tobramycin	413	0.5%
31	Meperidine	397	0.5%
32	Tolvaptan	387	0.5%
33	Loratadine / Pseudoephedrine Sulfate	383	0.5%
34	Dolutegravir	369	0.4%
35	Abacavir	359	0.4%
36	Aflibercept	355	0.4%
37	Psyllium Husk	345	0.4%
38	Phenobarbital	314	0.4%
39	Acetaminophen, Aspirin, / Caffeine	312	0.4%
40	Voclosporin	309	0.4%
41	Ganciclovir	307	0.4%
42	Brivaracetam	291	0.3%
43	Posaconazole	273	0.3%
44	Acetaminophen, Aspirin (Nsaid) / Caffeine	272	0.3%
45	Suvorexant	213	0.3%
46	Docosanol	206	0.2%
47	Crisaborole	203	0.2%
48	Ranolazine	193	0.2%
49	Glycerin, Lidocaine	187	0.2%
50	Guanfacine	178	0.2%
51	Vigabatrin	176	0.2%
52	Micafungin	159	0.2%
53	Testosterone Cypionate	150	0.2%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. The presence of a drug in this list does not mean the drug caused product use issue. Always consult your healthcare provider.